The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Open accessAbstract
PURPOSE: SARC024 is a phase II clinical trial of the multikinase inhibitor regorafenib in specific sarcoma subtypes, including advanced osteosarcoma. We hypothesized that regorafenib would improve progression-free survival (PFS) in patients with sarcoma and report the results of the osteosarcoma cohort. PATIENTS AND METHODS: This trial enrolled patients with progressive metastatic osteosarcoma with measurable disease by RECIST who had received at least one prior line of therapy. Patients were randomly assigned at a ratio of one to one to regorafenib or placebo. Crossover was allowed at time of disease progression. PFS was the primary end point of the study, which was powered to detect a difference of at least 3 months in median PFS. RESULTS: Forty-two patients from 12 centers were enrolled between September 2014 and May 2018. Median age was 37 years (range, 18 to 76 years). Patients had received an average of 2.3 prior therapy regimens. Ten patients receiving placebo crossed over to active drug at time of progression. Study enrollment was stopped early, after a data safety monitoring committee review. Median PFS was significantly improved with regorafenib versus placebo: 3.6 months (95% CI, 2.0 to 7.6 months) versus 1.7 months (95% CI, 1.2 to 1.8 months), respectively (hazard ratio, 0.42; 95% CI, 0.21 to 0.85; P = .017). In the context of the crossover design, there was no statistically significant difference in overall survival. Fourteen (64%) of 22 patients initially randomly assigned to regorafenib experienced grade 3 to 4 events attributed to treatment, including one grade 4 colonic perforation. CONCLUSION: The study met its primary end point, demonstrating activity of regorafenib in patients with progressive metastatic osteosarcoma. No new safety signals were observed. Regorafenib should be considered a treatment option for patients with relapsed metastatic osteosarcoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, clinical trials involving TKIs alone are typically with median PFS ranging from 4 to 6 months accompanied with inevitable development of secondary drug resistance1–5.”
From Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, PFS data for IE in relapsed or refractory osteosarcoma were published several decades before the OLIE study46; thus, the PFS estimate for IE relied on limited historical data from other clinically active agents,15,35,36 and IE performed better than expected relative to these assumptions.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“demonstrating a median progression‐free survival (PFS) of 14.8 weeks in Ewing sarcoma, 10 a median PFS of 3.6 months in osteosarcoma, 11 and a nonprogressive rate at 3 months of 54%, significantly better than results with placebo in chondrosarcoma. 12”
From Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial (2025) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies have demonstrated that multi-targeted tyrosine kinase inhibitor (TKIs) can induce varying degrees of objective responses and prolong progression-free survival (PFS)1–5.”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“BS on average show very low TMB: 0.79–1.96 mutations/Mbase in osteosarcoma, 11 , 17 , 18 , 19 ∼0.2 mutations/Mbas in Ewing sarcoma 19 , 20 and <5 mutations/Mbase in chondrosarcoma with some correlation with grade. 21”
From Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial (2025) · cites this paper as [11]
Experimental — accuracy not yet measured
In the citing paper
“Objective response rates were low at 10-15%.”
From Osteosarcoma (2022) · cites this paper as [146]
In the citing paper
“Of note, dose interruptions and reductions of MTKIs have been frequent across these trials secondary to common toxic effects of this drug class, including hand-foot rash syndrome (palmar-plantar erythrodysesthesia), gastrointestinal toxic effects and hypertension 146,147,148,149,150,151 .”
From Osteosarcoma (2022) · cites this paper as [146]
In the citing paper
“Four-month progression-free survival (PFS) ranged from 35% to 70% 146,147,148,149,151 .”
From Osteosarcoma (2022) · cites this paper as [146]
In the citing paper
“Prospective clinical trials evaluated the MTKIs sorafenib, regorafenib, cabozantinib, lenvatinib and apatinib as single agents in patients with relapsed or refractory osteosarcoma, with most enrolled patients falling in the adult age range 146,147,148,149,150,151 (Table 2).”
From Osteosarcoma (2022) · cites this paper as [146]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452 · cited 2×
“Six of 22 patients in SARC028 achieved stable disease, resulting in 12-week PFS of 32%, suggesting activity worth further evaluation of immune checkpoint inhibitors in osteosarcoma.(21) Time Since Start of Crossover Treatment (months) C”
BackgroundSelf-citationLink, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,203
D'Angelo, S. P., Mahoney, M. R., Van Tine, B. A., Atkins, J., Milhem, M. M., Jahagirdar, B. N., Antonescu, C. R., Horvath, E., Tap, W. D., Schwartz, G. K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30006-8 · Cited by 759
Osteosarcoma, Chondrosarcoma, and Chordoma
Whelan, J., & Davis, L. E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.1743 · Cited by 477
Self-citationBielack, S. S., Smeland, S., Whelan, J. S., Marina, N., Jovic, G., Hook, J. M., Krailo, M. D., Gebhardt, M., Pápai, Z., Meyer, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0734 · Cited by 422
Atkins, M. B., Plimack, E. R., Puzanov, I. J., Fishman, M., McDermott, D. F., Cho, D. C., Vaishampayan, U. N., George, S., Olencki, T. E., Tarazi, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30081-0 · Cited by 372
Grignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P. G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr151 · Cited by 359
Grignani, G., Palmerini, E., Ferraresi, V., D’Ambrosio, L., Bertulli, R., Asaftei, S. D., Tamburini, A., Pignochino, Y., Sangiolo, D., Marchesi, E., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71136-2 · Cited by 343
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–267 of 267
Paediatric therapeutic development workshop on osteosarcoma
Baxter, J. S., Montiel-Equihua, C., Molenaar, J. J., Berlanga, P., Bishop, M. W., Blanc, P., Campbell-Hewson, Q., Casanova, M., Cortés‐Ciriano, I., Crompton, B. D., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03572-1 · Cited by 1
Self-citationUmeda, K., Sakamoto, A., Noguchi, T., Uchihara, Y., Kobushi, H., Akazawa, R., Ogata, H., Saida, S., Kato, I., Hiramatsu, H., et al. (2022) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000002521 · Cited by 1
Morakote, W., Adams, L. C., Ramasamy, S. K., Spunt, S. L., Baratto, L., Liang, T., & Daldrup-Link, H. E. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30629 · Cited by 1
Update in Solid Tumors of Childhood
Shrivastava, N., & O'Neill, A. F. (2023) · Springer eBooks · doi:10.1007/978-3-031-41542-5_25 · Cited by 1
Chantre-Justino, M., Silvestre, R. T., Castro, T. D., Luz, E., Pinheiro, R., Caruso, A. C., Lopes, A. C. D. S., Meohas, W., Alves, G., & Ornellas, M. H. (2025) · Biomedical Reports · doi:10.3892/br.2025.1920 · Cited by 1
Wang, K., Silli, E. K., Lv, H., & Song, R. (2025) · Drug Development Research · doi:10.1002/ddr.70207 · Cited by 1
Systemic Treatment of Ewing Sarcoma: Current Options and Future Perspectives
Moreno, J. D., Papageorgiou, G., Gazouli, I., & Kyriazoglou, A. I. (2021) · Forum of Clinical Oncology · doi:10.2478/fco-2021-0005 · Cited by 1
Systemische Therapie von Osteosarkomen
Bielack, S., Reichardt, P., Lindner, L. H., & Hecker‐Nolting, S. (2022) · Die Onkologie · doi:10.1007/s00761-022-01119-6 · Cited by 1
Radiation Therapy for Oligometastatic Sarcomas
Wong, P., Charlson, J. A., Masucci, L., & Bahig, H. (2022) · Practical guides in radiation oncology · doi:10.1007/978-3-031-06706-8_4 · Cited by 1
Goldsmith, R. M., Xing, J. L., Heal, C., de la Maza, M. C., & Stea, B. (2024) · Advances in Radiation Oncology · doi:10.1016/j.adro.2024.101517 · Cited by 1
Novel agents in a young patient with osteosarcoma: A short review
Steinbrecher, O., Brodowicz, T., & Lamm, W. W. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00728-y · Cited by 1
Complications of biologic therapy for pediatric cancer – What the surgeon needs to know
Malek, M. M. (2019) · Seminars in Pediatric Surgery · doi:10.1016/j.sempedsurg.2019.150863
The Role of Systemic Therapies in the Management of Bone Sarcoma
To, Y. H., Orme, L. M., & Lewin, J. H. (2020) · Springer eBooks · doi:10.1007/978-981-15-9414-4_12
Osteosarcoma of rib treated with regorafenib: a case report
SAKAR, O., Metin, C. U., Şahin, A. B., Evrensel, T., & Gebitekin, C. (2021) · Turkish Journal of Internal Medicine · doi:10.46310/tjim.875951
Chemotherapy for Pelvic Bone Tumors
Brunello, A., & Zagonel, V. (2021) · Springer eBooks · doi:10.1007/978-3-030-77007-5_19
New therapeutic advances of bone sarcomas
Blay, J., Brahmi, M., Marec‐Bérard, P., Corradini, N., & Dufresne, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821666-8.00072-4
Identification of new therapeutic targets of bone cancers by proteomic strategies
Wood, S. L., López-Guajardo, A., & Brown, J. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821666-8.00005-0
Zhang, C., Wu, H., Xu, G., Ma, W., Qi, L., Li, Z., & Zhang, J. (2021) · Research Square · doi:10.21203/rs.3.rs-1071152/v1
Cusano, E., Wong, C., Taguedong, E., Vaska, M. M., Abedin, T., Nixon, N. A., Karim, S., Tang, P. A., Heng, D. Y. C., & Ezeife, D. A. (2021) · Current Oncology · doi:10.3390/curroncol28060412
Colletti, M., & Cruz, M. (2010)
"The Current State of Target Therapy for Subtypes of Gastrointestinal Stromal Tumors"
Zong, L. (2021) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2021.39.006292
Lu, Y., Long, Z., Huang, M., Li, M., Li, J., Wang, Z., & Zhang, H. (2021) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pacr.2.2021.5
Zhang, C., Wu, H., Xu, G., Ma, W., Qi, L., Li, Z., & Zhang, J. (2022) · Research Square · doi:10.21203/rs.3.rs-1071152/v2
Isakoff, M. S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736596348.793567988
Systemische Therapie von Osteosarkomen*
Bielack, S., Reichardt, P., Lindner, L. H., & Hecker‐Nolting, S. (2023) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-023-9846-8
Olsen, H. E., Liu, K. X., Frazier, A. L., O'Neill, A. F., Janeway, K. A., DuBois, S. G., & Shulman, D. S. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30652
Special Issue: “Pediatric Orthopedic Malignancy: Types, Symptoms, and Treatment”
Aiba, H., Miwa, S., Murakami, H., & Kimura, H. J. (2023) · Children · doi:10.3390/children10091545
Alves, A. F., Oliveira, H. G. A., da Silva, K. A. M., de Oliveira, E. C. L., do Carmo, M. F., de Rezende, M. J., & Loth, E. A. (2024) · Research Society and Development · doi:10.33448/rsd-v13i2.45061
Zhou, S., Liu, Q., Fu, Y., Du, L., Bao, Q., Zhang, Z., Xu, Z., Yan, F., Li, M., Liu, R., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101993
Generalities of Orthopaedic Oncology
Zumárraga, J. P., & Baptista, A. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-30518-4_179
Current status and future directions of systemic therapy in high-grade bone sarcomas
Machak, G. N. (2024) · N N Priorov Journal of Traumatology and Orthopedics · doi:10.17816/vto624147
Anlotinib/Apatinib Plus Chemotherapy as Second-Line or Later Therapy in Advanced OsteosarcomaPreprint
Song, H., Han, K., Yang, Y., Sun, X., Zhou, M., Tian, C., Zhu, H., Chen, Q., Min, D., & Li, B. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4880343
Genetic and molecular profiling in bone sarcomas: advancing personalized treatment approaches
Dhruv, G., Raj, A. N., & Sharma, S. (2024) · InterConf · doi:10.51582/interconf.19-20.08.2024.018
Prolonged clinical response is possible with regorafenib in refractory osteosarcoma: A case report
Dursun, B., Köksoy, E. B., & Utkan, G. (2024) · Journal of Clinical and Experimental Investigations · doi:10.29333/jcei/15645
Wu, W., Zheng, W., Pan, W., Chen, F., & Jiang, L. (2025) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2025058118
Kidd, A. C., Vesey, A. T., Vohra, S., Kochman, A., & Armstrong, S. (2025) · The Royal College of Radiologists Open · doi:10.1016/j.rcro.2025.100344
Wong, K. P. L., Banjar, M. A., Hallinan, J. T. P. D., Odoño, E. G., Lee, V. K. M., Soh, S. Y., & Puhaindran, M. E. (2025) · Springer eBooks · doi:10.1007/978-981-96-2163-7_10
Riva, F., Vari, S., Onesti, C. E., Covello, R., Scuderi, S., Ceddia, S., Fiore, M. R., Anelli, V., Strippoli, S., & Ferraresi, V. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1604056
Mordechai, O., Ilivitzki, A., Vlodavsky, E., Arush, M. W. B., & Postovsky, S. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.32007
Zhang, C., Wu, H., Xu, G., Xu, Y., Ma, W., Li, Z., & Zhang, J. (2023) · Figshare · doi:10.6084/m9.figshare.23293320
Zhang, C., Wu, H., Xu, G., Xu, Y., Ma, W., Li, Z., & Zhang, J. (2023) · Figshare · doi:10.6084/m9.figshare.23293323
Zhang, C., Wu, H., Xu, G., Xu, Y., Ma, W., Li, Z., & Zhang, J. (2023) · Figshare · doi:10.6084/m9.figshare.23293317
Wang, H., Jin, X., Gao, Y., He, X., Xu, Y., Mu, H., Jiang, Y., Wang, Z., Yu, C., Zhang, T., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26588022
Zhou, Y., Li, M., Zhang, B., Yang, C., Wang, Y., Zheng, S., Tang, L., Zhou, C., Qian, G., Huang, Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24669876
Huang, G., Zhang, X., Xu, Y., Chen, S., Cao, Q., Liu, W. G., Fu, Y., Jia, Q., Shen, J., Yin, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26670855
Rahmanian, M., Khoropanah, S., Vatankhah, A., Moghaddam, S. H., Bastamie, E. A., Roashanzamir, S., Sharifabad, A. R., & Ganji, R. (2025) · medRxiv · doi:10.1101/2025.08.04.25332569
Bayraktar, O., Eroğlu, S., Bharadwaj, S., Farooqı, A. A., Gözüaçık, D., & Kutlu, Ö. (2026) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70257
Xie, X., Bian, Y., Yang, X., Zhang, Y., Yin, J., & Shen, J. (2026) · Antibody Therapeutics · doi:10.1093/abt/tbag007
Utilisation de miRNAs thérapeutiques pour traiter les chondrosarcomes et les ostéosarcomes
Veys, C. (2021) · theses.fr (ABES) · doi:10.70675/7a59188ez7981z4d53za4fdz22a6b5deaaad
Gustafson, D. L., Early, K., Morales, M. A., Poplawski, K. A., Das, S., & Duval, D. L. (2026) · Veterinary and Comparative Oncology · doi:10.1111/vco.70074
What’s new in pediatric bone sarcomas and benign bone tumors
von der Weid, N., Baumhoer, D., & Krieg, A. H. (2026) · Journal of Children s Orthopaedics · doi:10.1177/18632521261444250
Abid, A., Noor, M., Saad, A., Farhat, S., Sikander, N., & Ahmad, T. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000005065
Ganem, G. C. A., Chambi, J. T., Pagan, B. M., Cuffini, S. L., & Lopes, J. H. (2026) · International Journal of Applied Ceramic Technology · doi:10.1111/ijac.70210
Pan, Q., Xu, B., Zhang, L., Li, H., Zhao, J. S., Wen, X., Yang, J., Weng, D., Peng, R., Zhang, P., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116871
Precision oncology in the treatment of patients with bone sarcomas: an up-to-date narrative review
Yarar, S., & Tsagozis, P. (2026) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2026.1002396
Emerging Treatments in Bone Tumors: Lessons Learned from the ESMO Annual Meeting
Kotapati, S., Manoharan, M., & Palmerini, E. (2026) · Biomolecules · doi:10.3390/biom16081167
Burke, Z. D. C., Lin‐Rahardja, K., Mandel, G., Imamura, J., Durmaz, A., Nowak, E., Hitomi, M., & Scott, J. G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.10.743977
BAM15 Enhances Regorafenib Cytotoxicity in a Canine Osteosarcoma Cell Model
Dolnicka, A., Marcinkowska, K. A., Obmińska‐Mrukowicz, B., Fosse, V., Raciborska, A., & Śmieszek, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27209121
Fidan, M. C., Uzundere, F. K., Biter, S., Durnalı, A., Kalacı, E., Bükün, H. O., Kocaaslan, E., Eniseler, E. B., Durukan, B. M., Tünbekici, S., et al. (2026) · JCO Global Oncology · doi:10.1200/go-26-00317
Osteosarcoma Across the Age Spectrum: Why Outcomes Diverge and Trials Must Adapt
Collins, S. H., & Matushansky, I. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187017
Qin, J. J., Bae, S., Luen, S. J., Hamilton, A., Orme, L. M., Andrew, E. C., Connolly, E. A., & Lewin, J. H. (2026) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.70180
Makkawi, R., Halsey, C. M. R., Murthy, V., Manalo, E. C., Cros, H., Yi, X., Cartier, J. M., Chang, M., Flory, M. R., Guptell, K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.30.755770
Pathobiology and Precision Management of Benign and Malignant Bone Tumors: A Narrative Review
Zaidi, A. R. Z., Samhan, S. M., Alhammad, L. A., Aldakhil, A. M., Al-Mutawa, A. M., Al-Shakhs, M. A., Almohaily, F. O., Alhabdan, H. A., Badahdah, M. M., Asiri, A. Y., et al. (2026) · Cureus · doi:10.7759/cureus.117843
Spatial ligand–receptor circuits in osteosarcoma: immune resistance in bone and lung niches
Qiu, Y., Deng, S., Junfeng, Z., Tan, Q., Pan, Y., Li, E., Ren, K., & Wu, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1932933
Xie, L., Yao, W., Hua, Y., Luo, W., Tu, C., Wang, J., Chen, J., Li, B., Zhu, D., Li, X., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.10.1284 · Cited by 1
Metadata
- Authors
- Davis, L. E., Bolejack, V., Ryan, C. W., Ganjoo, K. N., Loggers, E. T., Chawla, S., Agulnik, M., Livingston, M. B., Reed, D., Keedy, V., Rushing, D., Okuno, S., Reinke, D. K., Riedel, R. F., Attia, S., Mascarenhas, L., & Maki, R. G.
- Affiliations
- Oregon Health & Science University (US)
- Cancer Research And Biostatistics (US)
- Stanford Cancer Institute (US)
- Fred Hutch Cancer Center (US)
- Sarcoma Oncology Center (US)
- Northwestern University (US)
- Levine Cancer Institute (US)
- Moffitt Cancer Center (US)
- Vanderbilt University (US)
- Indiana University Bloomington (US)
- Mayo Clinic (US)
- Sarcoma Alliance for Research through Collaboration (US)
- Duke Medical Center (US)
- University of Southern California (US)
- Northwell Health (US)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2019-06-01
- Volume
- 37
- Issue
- 16
- Pages
- 1424-1431
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC7799443
- OpenAlex
- W2941090871
- Cited by
- 268
- References
- 27
- Citations by year
- 2026: 27 · 2025: 29 · 2024: 35 · 2023: 52 · 2022: 36 · 2021: 44 · 2020: 35 · 2019: 9
- FWCI
- 22.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Funders
- National Cancer Institute (P30CA076292, P30CA014089)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- regorafenib, metastatic osteosarcoma, multikinase inhibitor, progression-free survival, relapsed sarcoma, crossover design, overall survival, drug safety, colonic perforation
- MeSH terms
- Progression-Free Survival, Adolescent, Adult, Aged, Antineoplastic Agents, Bone Neoplasms, Double-Blind Method, Female, Humans, Male, Middle Aged, Phenylurea Compounds, Pyridines, Osteosarcoma, Time Factors, United States, Disease Progression, Cross-Over Studies, Protein Kinase Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
